Euroimmun US  |  Products  |  Endocrinology  |  Hypertension  |  Endocrine hypertension

Endocrine hypertension

Biochemical analysis aligned with Endocrine Society guidelines¹˒²
For diagnosing primary aldosteronism and screening secondary hypertension

Demonstrated clinical application
Adult reference ranges and clinical cutoffs available for both supine and upright positions

Efficient workflow
ARR can be determined in a single plasma sample tube

Dual platform flexibility:
Both automated ChLIA and traditional ELISA options for varied throughput needs

Background

Hypertension is a condition that affects 120 million individuals, accounting for nearly half of Americans. The condition is characterized by high blood pressure greater than 130/80 mmHg.3 Hypertension can be classified as primary (essential), in around 80% of hypertensive patients; and secondary, in around the remaining 20% of hypertensive patients.3 1 in 3 people worldwide will develop hypertension regardless of age and gender. The leading cause of secondary hypertension is the endocrine etiology, primary aldosteronism.1 In primary aldosteronism, excess aldosterone secretion by the adrenal gland suppresses renin levels within the Renin-Angiotensin-Aldosterone System (RAAS)—resulting in renal sodium retention, increase in volume, elevated blood pressure, and in more serious forms, hypokalemia.2 Patients with primary aldosteronism are at a higher risk of heart disease, stroke, renal disease and reduced psychological well-being compared to their essential hypertension counterparts.2 Consequently, assessment of the RAAS is essential for diagnostic and therapeutic purposes.4 Other common causes of secondary hypertension include obstructive sleep apnea, chronic kidney disease (CKD), drug or alcohol use, and renovascular hypertension.

Diagnosis of primary aldosteronism and hypertension

Our endocrine hypertension portfolio can aid in the diagnosis of primary aldosteronism, the leading cause of secondary hypertension in the US.1,2 The plasma aldosterone/renin ratio (ARR) is used to detect possible cases of primary aldosteronism in patients with sustained high blood pressure—potassium is also assessed to aid in the accurate interpretation of aldosterone.1,2,5 Both aldosterone and renin should be measured to determine the ARR. Plasma aldosterone measurements are used in the diagnosis and treatment of primary aldosteronism, hypertension caused by primary aldosteronism, selective hyperaldosteronism, edematous states and other conditions of electrolyte balance.1,6 Plasma renin measurement is important in stratifying the diagnosis of the two most common forms of secondary hypertension which are primary aldosteronism and renovascular hypertension.1,3 Plasma renin evaluation can also help in selecting the most appropriate antihypertensive treatment.

Product description

  • Adult reference ranges available for both supine and upright positions.
  • Demonstrated clinical application with validated Aldo Renin Ratio (ARR) and suppression test cut-offs.5
  • Supports the diagnosis of primary aldosteronism and secondary hypertension.1-3
  • All ChLIA assays are fully automated and reagents come ready-to-use.

References

  1. Farah, M. H. et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism. J Clin Endocrinol Metab 110, e2833-e2844, doi:10.1210/clinem/dgaf290 (2025).
  2. Adler, G. K. et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 110, 2453-2495, doi:10.1210/clinem/dgaf284 (2025).
  3. Jones, D. W. et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 152, doi:10.1161/CIR.0000000000001356 (2025).
  4. Ménard, J. l. et al. Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement. Clinical Chemistry 55, 867-877, doi:10.1373/clinchem.2008.118000 (2009).
  5. Manolopoulou, J. et al. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens 33, 2500-2511, doi:10.1097/HJH.0000000000000727 (2015).
  6. Bidlingmaier, M. et al. Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. Clinical Chemistry 52, 1749-1755, doi:10.1373/clinchem.2006.068502 (2006).

Endocrine hypertension products

For in vitro diagnostic use.

For a list of all the products
Euroimmun offers please visit our Product Finder

Contact our Autoimmune product team
for further details and information

2026 Euroimmun US

Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap